Ashok and Rita Patel Institute of Integrated Study and Research in Biotechnology and Allied Sciences, ADIT Campus, New Vallabh Vidyanagar, 388121, Anand, Gujarat, India.
Muljibhai Patel Urological Hospital, Dr. V.V. Desai Road, Nadiad, 387001, Gujarat, India.
Mol Biol Rep. 2021 Nov;48(11):7193-7201. doi: 10.1007/s11033-021-06711-4. Epub 2021 Sep 21.
Nephrotic syndrome appears as a group of symptoms like proteinuria, edema and hyperlipidemia. Identification of monogenic forms revealed the physiology and pathogenesis of the SRNS.
We performed Illumina panel sequencing of seven genes in 90 Indian patients to determine the role of these genetic mutations in nephrotic syndrome prognosis. Samtool was used for variants calling, and SnpEff and Snpsift did variants annotation. Clinical significance and variant classification were performed by the ClinVar database. In SSNS and SRNS patients, we found 0.78% pathogenic and 3.41% likely pathogenic mutations. Pathogenic mutations were found in LAMB2, LMX1B and WT1 genes, while likely pathogenic mutations were found in (6/13) LAMB2, (2/13) LMX1B, (2/13) TRPC6, (2/13) PTPRO and (1/13) PMM2 genes. Approximately 46% likely pathogenic mutations were contributed to the LAMB2 gene in SSNS and SRNS patients. We also detect 30 VUS (variants of uncertain significance), which were found (17/30) pathogenic and (13/30) likely pathogenic by different prediction tools.
Multigene panels were used for genetic screening of heterogeneous disorders like nephrotic syndrome in the Indian population. We found pathogenic, likely pathogenic and certain VUS, which were responsible for the pathogenesis of the disease. Therefore, mutational analysis of SSNS and SRNS is necessary to avoid adverse effects of corticosteroids, modify the intensity of immunosuppressing agents, and prevent the disease's progression.
肾病综合征表现为蛋白尿、水肿和高脂血症等一组症状。单基因形式的鉴定揭示了 SRNS 的生理学和发病机制。
我们对 90 名印度患者的七个基因进行了 Illumina 面板测序,以确定这些基因突变在肾病综合征预后中的作用。Samtool 用于变体调用,SnpEff 和 Snpsift 用于变体注释。ClinVar 数据库用于临床意义和变体分类。在 SSNS 和 SRNS 患者中,我们发现了 0.78%的致病性和 3.41%的可能致病性突变。致病性突变发生在 LAMB2、LMX1B 和 WT1 基因中,而可能致病性突变发生在 (6/13) LAMB2、(2/13) LMX1B、(2/13) TRPC6、(2/13) PTPRO 和 (1/13) PMM2 基因中。在 SSNS 和 SRNS 患者中,大约 46%的可能致病性突变归因于 LAMB2 基因。我们还检测到 30 个 VUS(意义不确定的变体),不同的预测工具发现其中 (17/30) 为致病性,(13/30) 为可能致病性。
多基因面板用于对印度人群中像肾病综合征这样的异质性疾病进行遗传筛查。我们发现了致病性、可能致病性和某些 VUS,它们导致了疾病的发病机制。因此,对 SSNS 和 SRNS 进行突变分析对于避免皮质类固醇的不良反应、改变免疫抑制剂的强度以及预防疾病进展是必要的。